Breaking News

Canada Approves RSV Vaccine for People 50+

November 5, 2024 • 9:49 am CST
from Pixabay
(Precision Vaccinations News)

GSK today announced that AREXVY has been approved in Canada to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 50-59 years of age at increased risk for RSV disease.

In Canada, the vaccine was previously approved for use in adults aged 60 and older and is strongly recommended by the National Advisory Committee on Immunization (NACI) for all adults 75 years and older and those aged 60 and above in nursing homes and other chronic care facilities. NACI also recommends that adults aged 60-74 may consider RSV vaccination in consultation with a health care provider.

Michelle Horn, Interim Country Medical Director, GSK, said in a press release on November 5, 2024, “The natural age-related decline in immune function we all experience, which can increase our vulnerability to viruses like RSV, becomes more evident the older we get. Not surprisingly, the incidence of RSV-associated hospitalizations in adults starts to increase at the age of 50. For adults with underlying medical conditions, RSV can worsen these conditions and lead to serious consequences. We are proud to be the first to provide a vaccine to help protect Canadians aged 50-59 at increased risk of lower respiratory tract disease caused by RSV.”

Our Trust Standards: Medical Advisory Committee

Share